114 results on '"Skinner, Pamela J."'
Search Results
2. In Situ MHC Tetramer Staining : In situ tetramers
- Author
-
Skinner, Pamela J., Nagorsen, Dirk, editor, and Marincola, F.M., editor
- Published
- 2005
- Full Text
- View/download PDF
3. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques.
- Author
-
Pampusch, Mary S., Sevcik, Emily N., Quinn, Zoe E., Davey, Brianna C., Berg, James M., Gorrell-Brown, Ian, Abdelaal, Hadia M., Rakasz, Eva G., Rendahl, Aaron, and Skinner, Pamela J.
- Subjects
RHESUS monkeys ,CELLULAR therapy ,HIV infections ,IMMUNOGLOBULINS ,VIRAL load ,HIV status - Abstract
During chronic HIV and SIV infections, the majority of viral replication occurs within lymphoid follicles. In a pilot study, infusion of SIV-specific CD4-MBL-CAR-T cells expressing the follicular homing receptor, CXCR5, led to follicular localization of the cells and a reduction in SIV viral loads in rhesus macaques. However, the CAR-T cells failed to persist. We hypothesized that temporary disruption of follicles would create space for CAR-T cell engraftment and lead to increased abundance and persistence of CAR-T cells. In this study we treated SIV-infected rhesus macaques with CAR-T cells and preconditioned one set with anti-CD20 antibody to disrupt the follicles. We evaluated CAR-T cell abundance and persistence in four groups of SIVmac239-infected and ART-suppressed animals: untreated, CAR-T cell treated, CD20 depleted, and CD20 depleted/CAR-T cell treated. In the depletion study, anti-CD20 was infused one week prior to CAR-T infusion and cessation of ART. Anti-CD20 antibody treatment led to temporary depletion of CD20+ cells in blood and partial depletion in lymph nodes. In this dose escalation study, there was no impact of CAR-T cell infusion on SIV viral load. However, in both the depleted and non-depleted animals, CAR-T cells accumulated in and around lymphoid follicles and were Ki67+. CAR-T cells increased in number in follicles from 2 to 6 days post-treatment, with a median 15.2-fold increase in follicular CAR-T cell numbers in depleted/CAR-T treated animals compared to an 8.1-fold increase in non-depleted CAR-T treated animals. The increase in CAR T cells in depleted animals was associated with a prolonged elevation of serum IL-6 levels and a rapid loss of detectable CAR-T cells. Taken together, these data suggest that CAR-T cells likely expanded to a greater extent in depleted/CAR-T cell treated animals. Further studies are needed to elucidate mechanisms mediating the rapid loss of CAR-T cells and to evaluate strategies to improve engraftment and persistence of HIV-specific CAR-T cells. The potential for an inflammatory cytokine response appears to be enhanced with anti-CD20 antibody treatment and future studies may require CRS control strategies. These studies provide important insights into cellular immunotherapy and suggest future studies for improved outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection
- Author
-
Li, Qingsheng, Skinner, Pamela J., Ha, Sang-Jun, Duan, Lijie, Mattila, Teresa L., Hage, Aaron, White, Cara, Barber, Daniel L., O'Mara, Leigh, Southern, Peter J., Reilly, Cavan S., Carlis, John V., Miller, Christopher J., Ahmed, Rafi, and Haase, Ashley T.
- Subjects
Virus diseases -- Patient outcomes ,Immune response -- Research ,Science and technology - Abstract
In the early stages of viral infection, outcomes depend on a race between expansion of infection and the immune response generated to contain it. We combined in situ tetramer staining with in situ hybridization to visualize, map, and quantify relationships between immune effector cells and their targets in tissues. In simian immunodeficiency virus infections in macaques and lymphocytic choriomeningitis virus infections in mice, the magnitude and timing of the establishment of an excess of effector ceils versus targets were found to correlate with the extent of control and the infection outcome (i.e., control and clearance versus partial or poor control and persistent infection). This method highlights the importance of the location, timing, and magnitude of the immune response needed for a vaccine to be effective against agents of persistent infection, such as HIV-1.
- Published
- 2009
5. Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice
- Author
-
Skinner, Pamela J., Vierra-Green, Cynthia A., Emamian, Effat, Zoghbi, Huda Y., and Orr, Harry T.
- Published
- 2002
- Full Text
- View/download PDF
6. CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.
- Author
-
Pampusch, Mary S., Abdelaal, Hadia M., Cartwright, Emily K., Molden, Jhomary S., Davey, Brianna C., Sauve, Jordan D., Sevcik, Emily N., Rendahl, Aaron K., Rakasz, Eva G., Connick, Elizabeth, Berger, Edward A., and Skinner, Pamela J.
- Subjects
T cells ,CYTOTOXIC T cells ,SIMIAN immunodeficiency virus ,HIV ,LYMPHOID tissue ,RHESUS monkeys ,CHIMERIC antigen receptors - Abstract
During chronic human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) infection prior to AIDS progression, the vast majority of viral replication is concentrated within B cell follicles of secondary lymphoid tissues. We investigated whether infusion of T cells expressing an SIV-specific chimeric antigen receptor (CAR) and the follicular homing receptor, CXCR5, could successfully kill viral-RNA
+ cells in targeted lymphoid follicles in SIV-infected rhesus macaques. In this study, CD4 and CD8 T cells from rhesus macaques were genetically modified to express antiviral CAR and CXCR5 moieties (generating CAR/CXCR5-T cells) and autologously infused into a chronically infected animal. At 2 days post-treatment, the CAR/CXCR5-T cells were located primarily in spleen and lymph nodes both inside and outside of lymphoid follicles. Few CAR/CXCR5-T cells were detected in the ileum, rectum, and lung, and no cells were detected in the bone marrow, liver, or brain. Within follicles, CAR/CXCR5-T cells were found in direct contact with SIV-viral RNA+ cells. We next infused CAR/CXCR5-T cells into ART-suppressed SIV-infected rhesus macaques, in which the animals were released from ART at the time of infusion. These CAR/CXCR5-T cells replicated in vivo within both the extrafollicular and follicular regions of lymph nodes and accumulated within lymphoid follicles. CAR/CXR5-T cell concentrations in follicles peaked during the first week post-infusion but declined to undetectable levels after 2 to 4 weeks. Overall, CAR/CXCR5-T cell-treated animals maintained lower viral loads and follicular viral RNA levels than untreated control animals, and no outstanding adverse reactions were noted. These findings indicate that CAR/CXCR5-T cell treatment is safe and holds promise as a future treatment for the durable remission of HIV. Author summary: A person infected with human immunodeficiency virus (HIV) has replicating virus concentrated within the follicles of lymphoid tissues. The cells needed to clear the infection, cytotoxic T lymphocytes, have limited access to follicles and, thus, the cytotoxic T lymphocytes are never completely able to clear all of the HIV from the body. In this study, we have produced immunotherapeutic T cells that home to follicles and clear infected cells. These T cells express a viral targeting chimeric antigen receptor (CAR) and a molecule called CXCR5, which leads to homing of the cells to follicles. Upon administration of these CAR T-cells to virus-infected primates, we found that the cells localized to the follicle, replicated, and directly interacted with infected cells. While the cells were not maintained in the animals for more than 4 weeks, most of the treated animals maintained lower levels of virus in the blood and follicles than untreated control animals. This study shows that this immunotherapy has potential as a treatment leading to long-term remission of HIV without the need for antiretroviral drugs. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Identification of genes that modify ataxin-1-induced neurodegeneration
- Author
-
Fernandez-Funez, Pedro, Nino-Rosales, Maria Laura, de Gouyon, Beatrice, She, Wei-Chi, Luchak, James M., Martinez, Pedro, Turiegano, Enrique, Benito, Jonathan, Capovilla, Maria, Skinner, Pamela J., McCall, Alanna, Canal, Inmaculada, Orr, Harry T., Zoghbi, Huda Y., and Botas, Juan
- Subjects
Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
Author(s): Pedro Fernandez-Funez [1, 2]; Maria Laura Nino-Rosales [1, 2]; Beatrice de Gouyon [1]; Wei-Chi She [1, 3]; James M. Luchak [1]; Pedro Martinez [1]; Enrique Turiegano [4]; Jonathan Benito [...]
- Published
- 2000
- Full Text
- View/download PDF
8. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures
- Author
-
Skinner, Pamela J., Koshy, Beena T., Cummings, Christopher J., Klement, Ivan A., Helin, Kara, Servadio, Antonio, Zoghbi, Huda Y., and Orr, Harry T.
- Published
- 1997
9. Immunophenotyping of Rhesus CMV‐Specific CD8 T‐Cell Populations.
- Author
-
Pomplun, Nicholas L., Vosler, Logan, Weisgrau, Kim L., Furlott, Jessica, Weiler, Andrea M., Abdelaal, Hadia M., Evans, David T., Watkins, David I., Matano, Tetsuro, Skinner, Pamela J., Friedrich, Thomas C., and Rakasz, Eva G.
- Abstract
A vaccine to ameliorate cytomegalovirus (CMV)‐related pathogenicity in transplantation patients is considered a top priority. A therapeutic vaccine must include components that elicit both neutralizing antibodies, and highly effective CD8 T‐cell responses. The most important translational model of vaccine development is the captive‐bred rhesus macaque (Macaca mulatta) of Indian origin. There is a dearth of information on rhesus cytomegalovirus (rhCMV)‐specific CD8 T cells due to the absence of well‐defined CD8 T‐cell epitopes presented by classical MHC‐I molecules. In the current study, we defined two CD8 T‐cell epitopes restricted by high‐frequency Mamu alleles: the Mamu‐A1*002:01 restricted VY9 (VTTLGMALY aa291‐299) epitope of protein IE‐1, and the Mamu‐A1*008:01 restricted NP8 (NPTDRPIP aa96‐103) epitope of protein phosphoprotein 65‐2. We developed tetramers and determined the level, phenotype, and functional capability of the two epitope‐specific T‐cell populations in circulation and various tissues. We demonstrated the value of these tetramers for in situ tetramer staining. Here, we first provided critical reagents and established a flow cytometric staining strategy to study rhCMV‐specific T‐cell responses in up to 40% of captive‐bred rhesus macaques. © 2020 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Gene expression alterations in brains of mice infected with three strains of scrapie
- Author
-
Race Richard E, Chesebro Bruce, Abbassi Hayet, Skinner Pamela J, Reilly Cavan, and Haase Ashley T
- Subjects
Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Background Transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal neurodegenerative disorders which occur in humans and various animal species. Examples include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in deer and elk, and scrapie in sheep, and experimental mice. To gain insights into TSE pathogenesis, we made and used cDNA microarrays to identify disease-associated alterations in gene expression. Brain gene expression in scrapie-infected mice was compared to mock-infected mice at pre-symptomatic and symptomatic time points. Three strains of mouse scrapie that show striking differences in neuropathology were studied: ME7, 22L, and Chandler/RML. Results In symptomatic mice, over 400 significant gene expression alterations were identified. In contrast, only 22 genes showed significant alteration in the pre-symptomatic animals. We also identified genes that showed significant differences in alterations in gene expression between strains. Genes identified in this study encode proteins that are involved in many cellular processes including protein folding, endosome/lysosome function, immunity, synapse function, metal ion binding, calcium regulation and cytoskeletal function. Conclusion These studies shed light on the complex molecular events that occur during prion disease, and identify genes whose further study may yield new insights into strain specific neuropathogenesis and ante-mortem tests for TSEs.
- Published
- 2006
- Full Text
- View/download PDF
11. In Situ MHC-tetramer Staining and Quantitative Analysis to Determine the Location, Abundance, and Phenotype of Antigen-specific CD8 T Cells in Tissues
- Author
-
Li, Shengbin, Mwakalundwa, Gwantwa, and Skinner, Pamela J.
- Subjects
Microscopy, Confocal ,Phenotype ,Immunology ,Histocompatibility Antigens Class I ,Humans ,CD8-Positive T-Lymphocytes ,Flow Cytometry ,Immunohistochemistry - Abstract
T cells are critical to many immunological processes, including detecting and eliminating virus-infected cells, preventing autoimmunity, assisting in B-cell and plasma-cell production of antibodies, and detecting and eliminating cancer cells. The development of MHC-tetramer staining of antigen-specific T cells analyzed by flow cytometry has revolutionized our ability to study and understand the immunobiology of T cells. While extremely useful for determining the quantity and phenotype of antigen-specific T cells, flow cytometry cannot determine the spatial localization of antigen-specific T cells to other cells and structures in tissues, and current disaggregation techniques to extract the T cells needed for flow cytometry have limited effectiveness in non-lymphoid tissues. In situ MHC-tetramer staining (IST) is a technique to visualize T cells that are specific for antigens of interest in tissues. In combination with immunohistochemistry (IHC), IST can determine the abundance, location, and phenotype of antigen-specific CD8 and CD4 T cells in tissues. Here, we describe a protocol to stain and enumerate antigen-specific CD8 T cells, with specific phenotypes located within specific tissue compartments. These procedures are the same that we used in our recent publication by Li et al., entitled "Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo." The methods described are broadly applicable because they can be used to localize, phenotype, and quantify essentially any antigen-specific CD8 T cell for which MHC tetramers are available, in any tissue.
- Published
- 2017
12. Past, Present and Potential Future Prion Disease Treatment Strategies
- Author
-
Skinner, Pamela J.
- Subjects
Medical / Infectious Diseases - Abstract
The prion diseases are rare and invariably fatal neurodegenerative diseases characterized by a unique, protein‐only pathogenesis. Mechanistically, the prion diseases result from the coerced conversion of a protease‐sensitive form of the cellular prion protein (PrPC) into a protease‐resistant infectious form (PrPres). This chapter reviews the past, present, and potentially future prion disease treatment strategies. This chapter begins with an introduction to prion diseases, the misfolding of prion proteins and what is known about this process, and then proceeds to discuss approaches for treatments. Regarding approaches to treat prion diseases, we discuss (1) small molecule inhibitors, (2) antiprion protein antibodies, (3) prion gene disruption, (4) targeting of the unfolded protein response, and (5) heterologous prion proteins. We elaborate on using heterologous prion proteins to treat prion diseases, as this is an area that we are pursuing. The chapter ends with thoughts on the future direction of prion disease treatment strategies and how these strategies might be applicable to other neurodegenerative diseases involving protein misfolding. The increasing awareness of the role of protein misfolding in many neurodegenerative processes makes the development of an effective treatment strategy for prion diseases a high priority.
- Published
- 2017
13. Low levels of SIV-specific CD8+ T cells in germinal centers characterizes acute SIV infection.
- Author
-
Li, Shengbin, Folkvord, Joy M., Kovacs, Katalin J., Wagstaff, Reece K., Mwakalundwa, Gwantwa, Rendahl, Aaron K., Rakasz, Eva G., Connick, Elizabeth, and Skinner, Pamela J.
- Subjects
CD8 antigen ,HIV prevention ,SIMIAN immunodeficiency virus diseases ,INFECTION prevention ,T cells - Abstract
CD8+ T cells play an important role in controlling of HIV and SIV infections. However, these cells are largely excluded from B cell follicles where HIV and SIV producing cells concentrate during chronic infection. It is not known, however, if antigen-specific CD8+ T cells are excluded gradually as pathogenesis progresses from early to chronic phase, or this phenomenon occurs from the beginning infection. In this study we determined that SIV-specific CD8+ T cells were largely excluded from follicles during early infection, we also found that within follicles, they were entirely absent in 60% of the germinal centers (GCs) examined. Furthermore, levels of SIV-specific CD8+ T cells in follicular but not extrafollicular areas significantly correlated inversely with levels of viral RNA+ cells. In addition, subsets of follicular SIV-specific CD8+ T cells were activated and proliferating and expressed the cytolytic protein perforin. These studies suggest that a paucity of SIV-specific CD8+ T cells in follicles and complete absence within GCs during early infection may set the stage for the establishment of persistent chronic infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Live SIV vaccine correlate of protection: local antibody production and concentration on the path of virus entry
- Author
-
Li, Qingsheng, Zeng, Ming, Duan, Lijie, Voss, James E., Smith, Anthony J., Pambuccian, Stefan, Shang, Liang, Wietgrefe, Stephen, Southern, Peter J., Reilly, Cavan S., Skinner, Pamela J., Zupancic, Mary L., Carlis, John V., Piatak, Michael, Waterman, Diane, Reeves, R. Keith, Masek-Hammerman, Katherine, Derdeyn, Cynthia A., Alpert, Michael D., Evans, David T., Kohler, Heinz, Muller, Sybille, Robinson, James, Lifson, Jeffrey D., Burton, Dennis R., Johnson, R. Paul, and Haase, Ashley T.
- Subjects
Mucous Membrane ,Vaccination ,SAIDS Vaccines ,Simian Acquired Immunodeficiency Syndrome ,HIV Infections ,Cervix Uteri ,Antibodies, Viral ,Vaccines, Attenuated ,Antibodies, Neutralizing ,Macaca mulatta ,Article ,HIV Envelope Protein gp41 ,Immunoglobulin G ,Antibody Formation ,Vagina ,HIV-1 ,Animals ,Female ,Simian Immunodeficiency Virus - Abstract
We sought design principles for a vaccine to prevent HIV transmission to women by identifying correlates of protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal model. We show that SIVmac239Δnef vaccination recruits plasma cells and induces ectopic lymphoid follicle formation beneath the mucosal epithelium in the rhesus macaque female reproductive tract. The plasma cells and ectopic follicles produce IgG antibodies reactive with viral envelope glycoprotein gp41 trimers, and these antibodies are concentrated on the path of virus entry by the neonatal Fc receptor (FcRn) in cervical reserve epithelium and in vaginal epithelium. This local antibody production and delivery system correlated spatially and temporally with the maturation of local protection against high dose pathogenic SIV vaginal challenge. Thus, designing vaccines to elicit production and concentration of antibodies at mucosal frontlines could aid development of an effective vaccine to protect women against HIV-1.
- Published
- 2014
15. Virus and CTL dynamics in the extrafollicular and follicular tissue compartments in SIV-infected macaques.
- Author
-
Wodarz, Dominik, Skinner, Pamela J., Levy, David N., and Connick, Elizabeth
- Subjects
- *
VIRUSES , *CYTOTOXIC T cells , *MACAQUES , *LYMPHOID tissue , *MATHEMATICAL models - Abstract
Data from SIV-infected macaques indicate that virus-specific cytotoxic T lymphocytes (CTL) are mostly present in the extrafollicular (EF) compartment of the lymphoid tissue, with reduced homing to the follicular (F) site. This contributes to the majority of the virus being present in the follicle and represents a barrier to virus control. Using mathematical models, we investigate these dynamics. Two models are analyzed. The first assumes that CTL can only become stimulated and expand in the extrafollicular compartment, with migration accounting for the presence of CTL in the follicle. In the second model, follicular CTL can also undergo antigen-induced expansion. Consistent with experimental data, both models predict increased virus compartmentalization in the presence of stronger CTL responses and lower virus loads, and a more pronounced rise of extrafollicular compared to follicular virus during CD8 cell depletion experiments. The models, however, differ in other aspects. The follicular expansion model results in dynamics that promote the clearance of productive infection in the extrafollicular site, with any productively infected cells found being the result of immigration from the follicle. This is not observed in the model without follicular CTL expansion. The models further predict different consequences of introducing engineered, follicular-homing CTL, which has been proposed as a therapeutic means to improve virus control. Without follicular CTL expansion, this is predicted to result in a reduction of virus load in both compartments. The follicular CTL expansion model, however, makes the counter-intuitive prediction that addition of F-homing CTL not only results in a reduction of follicular virus load, but also in an increase in extrafollicular virus replication. These predictions remain to be experimentally tested, which will be relevant for distinguishing between models and for understanding how therapeutic introduction of F-homing CTL might impact the overall dynamics of the infection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection.
- Author
-
Kiniry, Brenna E, Li, Shengbin, Ganesh, Anupama, Hunt, Peter W, Somsouk, Ma, Skinner, Pamela J, Deeks, Steven G, and Shacklett, Barbara L
- Published
- 2018
- Full Text
- View/download PDF
17. Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.
- Author
-
Haran, Kumudhini Preethi, Hajduczki, Agnes, Pampusch, Mary S., Mwakalundwa, Gwantwa, Vargas-Inchaustegui, Diego A., Rakasz, Eva G., Connick, Elizabeth, Berger, Edward A., and Skinner, Pamela J.
- Subjects
SIMIAN immunodeficiency virus ,CHIMERIC antigen receptors ,B cells - Abstract
There is a need to develop improved methods to treat and potentially cure HIV infection. During chronic HIV infection, replication is concentrated within T follicular helper cells (Tfh) located within B cell follicles, where low levels of virus-specific CTL permit ongoing viral replication. We previously showed that elevated levels of simian immunodeficiency virus (SIV)-specific CTL in B cell follicles are linked to both decreased levels of viral replication in follicles and decreased plasma viral loads. These findings provide the rationale to develop a strategy for targeting follicular viral-producing (Tfh) cells using antiviral chimeric antigen receptor (CAR) T cells co-expressing the follicular homing chemokine receptor CXCR5. We hypothesize that antiviral CAR/CXCR5-expressing T cells, when infused into an SIV-infected animal or an HIV-infected individual, will home to B cell follicles, suppress viral replication, and lead to long-term durable remission of SIV and HIV. To begin to test this hypothesis, we engineered gammaretroviral transduction vectors for co-expression of a bispecific anti-SIV CAR and rhesus macaque CXCR5. Viral suppression by CAR/CXCR5-transduced T cells was measured in vitro, and CXCR5-mediated migration was evaluated using both an in vitro transwell migration assay, as well as a novel ex vivo tissue migration assay. The functionality of the CAR/CXCR5 T cells was demonstrated through their potent suppression of SIV
mac239 and SIVE660 replication in in vitro and migration to the ligand CXCL13 in vitro, and concentration in B cell follicles in tissues ex vivo. These novel antiviral immunotherapy products have the potential to provide long-term durable remission (functional cure) of HIV and SIV infections. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. The B-Cell Follicle in HIV Infection: Barrier to a Cure.
- Author
-
Bronnimann, Matthew P., Skinner, Pamela J., and Connick, Elizabeth
- Subjects
DENDRITIC cells ,T cells ,LYMPHOID tissue - Abstract
The majority of HIV replication occurs in secondary lymphoid organs (SLOs) such as the spleen, lymph nodes, and gut-associated lymphoid tissue. Within SLOs, HIV RNA
+ cells are concentrated in the B-cell follicle during chronic untreated infection, and emerging data suggest that they are a major source of replication in treated disease as well. The concentration of HIV RNA+ cells in the B-cell follicle is mediated by several factors. Follicular CD4+ T-cell subsets including T-follicular helper cells and T-follicular regulatory cells are significantly more permissive to HIV than extrafollicular subsets. The B cell follicle also contains a large reservoir of extracellular HIV virions, which accumulate on the surface of follicular dendritic cells (FDCs) in germinal centers. FDC-bound HIV virions remain infectious even in the presence of neutralizing antibodies and can persist for months or even years. Moreover, the B-cell follicle is semi-immune privileged from CTL control. Frequencies of HIV- and SIV-specific CTL are lower in B-cell follicles compared to extrafollicular regions as the majority of CTL do not express the follicular homing receptor CXCR5. Additionally, CTL in the B-cell follicle may be less functional than extrafollicular CTL as many exhibit the recently described CD8 T follicular regulatory phenotype. Other factors may also contribute to the follicular concentration of HIV RNA+ cells. Notably, the contribution of NK cells and γδ T cells to control and/or persistence of HIV RNA+ cells in secondary lymphoid tissue remains poorly characterized. As HIV research moves increasingly toward the development of cure strategies, a greater understanding of the barriers to control of HIV infection in B-cell follicles is critical. Although no strategy has as of yet proven to be effective, a range of novel therapies to address these barriers are currently being investigated including genetically engineered CTL or chimeric antigen receptor T cells that express the follicular homing molecule CXCR5, treatment with IL-15 or an IL-15 superagonist, use of bispecific antibodies to harness the killing power of the follicular CD8+ T cell population, and disruption of the follicle through treatments such as rituximab. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection.
- Author
-
Miles, Brodie, Miller, Shannon M., Folkvord, Joy M., Levy, David N., Rakasz, Eva G., Skinner, Pamela J., and Connick, Elizabeth
- Subjects
T cells ,HIV infections ,VIRAL replication ,APOPTOSIS ,LYMPHOCYTES - Abstract
During chronic HIV infection, viral replication is concentrated in secondary lymphoid follicles. Cytotoxic CD8 T cells control HIV replication in extrafollicular regions, but not in the follicle. Here, we show CXCR5
hi CD44hi CD8 T cells are a regulatory subset differing from conventional CD8 T cells, and constitute the majority of CD8 T cells in the follicle. This subset, CD8 follicular regulatory T cells (CD8 TFR ), expand in chronic SIV infection, exhibit enhanced expression of Tim-3 and IL-10, and express less perforin compared to conventional CD8 T cells. CD8 TFR modestly limit HIV replication in follicular helper T cells (TFH ), impair TFH IL-21 production via Tim-3, and inhibit IgG production by B cells during ex vivo HIV infection. CD8 TFR induce TFH apoptosis through HLA-E, but induce less apoptosis than conventional CD8 T cells. These data demonstrate that a unique regulatory CD8 population exists in follicles that impairs GC function in HIV infection. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
20. Potential approaches for heterologous prion protein treatment of prion diseases.
- Author
-
Seelig, Davis M., Goodman, Patricia A., and Skinner, Pamela J.
- Published
- 2016
- Full Text
- View/download PDF
21. Treatment of Prion Disease with Heterologous Prion Proteins.
- Author
-
Skinner, Pamela J., Kim, Hyeon O., Bryant, Damani, Kinzel, Nikilyn J., Reilly, Cavan, Priola, Suzette A., Ward, Anne E., Goodman, Patricia A., Olson, Katherine, and Seelig, Davis M.
- Subjects
- *
PRION disease treatment , *XENOGRAFTS , *BOVINE spongiform encephalopathy , *SEQUENCE alignment , *PROTEASE inhibitors - Abstract
Prion diseases such as Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy in cattle, and scrapie in sheep are fatal neurodegenerative diseases for which there is no effective treatment. The pathology of these diseases involves the conversion of a protease sensitive form of the cellular prion protein (PrPC) into a protease resistant infectious form (PrPsc or PrPres). Both in vitro (cell culture and cell free conversion assays) and in vivo (animal) studies have demonstrated the strong dependence of this conversion process on protein sequence homology between the initial prion inoculum and the host’s own cellular prion protein. The presence of non-homologous (heterologous) proteins is often inhibitory to this conversion process. We hypothesize that the presence of heterologous prion proteins from one species might therefore constitute an effective treatment for prion disease in another species. To test this hypothesis, we infected mice intracerebrally with murine adapted RML-Chandler scrapie and treated them with heterologous prion protein (purified bacterially expressed recombinant hamster prion protein) or vehicle alone. Treated animals demonstrated reduced disease associated pathology, decreased accumulation of protease-resistant disease-associated prion protein, with delayed onset of clinical symptoms and motor deficits. This was concomitant with significantly increased survival times relative to mock-treated animals. These results provide proof of principle that recombinant hamster prion proteins can effectively and safely inhibit prion disease in mice, and suggest that hamster or other non-human prion proteins may be a viable treatment for prion diseases in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. In Situ Peptide-MHC-II Tetramer Staining of Antigen-Specific CD4+ T Cells in Tissues.
- Author
-
Dileepan, Thamotharampillai, Kim, Hyeon O., Cleary, P. Patrick, and Skinner, Pamela J.
- Subjects
MAJOR histocompatibility complex ,PEPTIDE analysis ,IMMUNOSTAINING ,CD4 antigen ,T cells ,TISSUE physiology - Abstract
The invention of peptide-MHC-tetramer technology to label antigen-specific T cells has led to an enhanced understanding of T lymphocyte biology. Here we describe the development of an in situ pMHC-II tetramer staining method to visualize antigen-specific CD4
+ T cells in tissues. This method complements other methods developed that similarly use MHC class II reagents to stain antigen-specific CD4+ T cells in situ. In this study, we used group A streptococcus (GAS) expressing a surrogate peptide (2W) to inoculate C57BL/6 mice, and used fresh nasal-associated lymphoid tissues (NALT) in optimizing the in situ staining of 2W:I-Ab specific CD4+ T cells. The results showed 2W:I-Ab tetramer-binding CD4+ T cells in GAS-2W but not GAS infected mice. This method holds promise to be broadly applicable to study the localization, abundance, and phenotype of antigen-specific CD4+ T cells in undisrupted tissues. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
23. Comparison of Vibratome and Compresstome sectioning of fresh primate lymphoid and genital tissues for in situ MHC-tetramer and immunofluorescence staining.
- Author
-
Abdelaal, Hadia M., Kim, Hyeon O., Wagstaff, Reece, Sawahata, Ryoko, Southern, Peter J., and Skinner, Pamela J.
- Subjects
IMMUNOFLUORESCENCE ,IMMUNOCYTOCHEMISTRY ,IMMUNOGLOBULINS ,GENITALIA ,TETRAMERS (Oligomers) - Abstract
Background For decades, the Vibratome served as a standard laboratory resource for sectioning fresh and fixed tissues. In skilled hands, high quality and consistent fresh unfixed tissue sections can be produced using a Vibratome but the sectioning procedure is extremely time consuming. In this study, we conducted a systematic comparison between the Vibratome and a new approach to section fresh unfixed tissues using a Compresstome. We used a Vibratome and a Compresstome to cut fresh unfixed lymphoid and genital non-human primate tissues then used in situ tetramer staining to label virus-specific CD8 T cells and immunofluorescent counter-staining to label B and T cells. We compared the Vibratome and Compresstome in five different sectioning parameters: speed of cutting, chilling capability, specimen stabilization, size of section, and section/staining quality. Results Overall, the Compresstome and Vibratome both produced high quality sections from unfixed spleen, lymph node, vagina, cervix, and uterus, and subsequent immunofluorescent staining was equivalent. The Compresstome however, offered distinct advantages; producing sections approximately 5 times faster than the Vibratome, cutting tissue sections more easily, and allowing production of larger sections. Conclusions A Compresstome can be used to generate fresh unfixed primate lymph node, spleen, vagina, cervix and uterus sections, and is superior to a Vibratome in cutting these fresh tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Location and Dynamics of the Immunodominant CD8 T Cell Response to SIVΔnef Immunization and SIVmac251 Vaginal Challenge.
- Author
-
Sasikala-Appukuttan, Arun K., Kim, Hyeon O., Kinzel, Nikilyn J., Hong, Jung Joo, Smith, Anthony J., Wagstaff, Reece, Reilly, Cavan, Piatak Jr, Michael, Lifson, Jeffrey D., Reeves, R. Keith, Johnson, R. Paul, Haase, Ashley T., and Skinner, Pamela J.
- Subjects
HIV prevention ,VIRUS disease transmission ,VIRAL vaccines ,CD8 antigen ,T cells ,IMMUNIZATION ,DRUG efficacy ,LYMPHOID tissue - Abstract
Live-attenuated SIV vaccines (LAVs) have been the most effective to date in preventing or partially controlling infection by wild-type SIV in non-human primate models of HIV-1 transmission to women acting by mechanisms of protection that are not well understood. To gain insights into mechanisms of protection by LAVs that could aid development of effective vaccines to prevent HIV-1 transmission to women, we used in situ tetramer staining to determine whether increased densities or changes in the local distribution of SIV-specific CD8 T cells correlated with the maturation of SIVΔnef vaccine-induced protection prior to and after intra-vaginal challenge with wild-type SIVmac251. We evaluated the immunodominant Mamu-A1*001:01/Gag (CM9) and Mamu-A1*001:01/Tat (SL8) epitope response in genital and lymphoid tissues, and found that tetramer+ cells were present at all time points examined. In the cervical vaginal tissues, most tetramer+ cells were distributed diffusely throughout the lamina propria or co-localized with other CD8 T cells within lymphoid aggregates. The distribution and densities of the tetramer+ cells at the portal of entry did not correlate with the maturation of protection or change after challenge. Given these findings, we discuss the possibility that changes in other aspects of the immune system, including the quality of the resident population of virus-specific effector CD8 T cells could contribute to maturation of protection, as well as the potential for vaccine strategies that further increase the size and quality of this effector population to prevent HIV-1 transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. GagCM9-Specific CD8+ T Cells Expressing Limited Public TCR Clonotypes Do Not Suppress SIV Replication In Vivo.
- Author
-
Vojnov, Lara, Martins, Mauricio A., Almeida, Jorge R., Ende, Zachary, Rakasz, Eva G., Reynolds, Matthew R., Leon, Enrique J., Weisgrau, Kim L., Burwitz, Benjamin J., Folkvord, Joy M., de Santana, Marlon G. Veloso, Neves, Patrícia C. Costa, Connick, Elizabeth, Skinner, Pamela J., Gostick, Emma, O'Connor, David H., Wilson, Nancy A., Bonaldo, Myrna C., Galler, Ricardo, and Price, David A.
- Subjects
SIMIAN immunodeficiency virus ,VIRAL replication ,MACAQUES ,T cells ,CLONE cells ,T cell receptors ,VIREMIA ,EPITOPES ,VACCINATION - Abstract
Several lines of evidence suggest that HIV/SIV-specific CD8
+ T cells play a critical role in the control of viral replication. Recently we observed high levels of viremia in Indian rhesus macaques vaccinated with a segment of SIVmac239 Gag (Gag45-269 ) that were subsequently infected with SIVsmE660. These seven Mamu-A*01+ animals developed CD8+ T cell responses against an immunodominant epitope in Gag, GagCM9, yet failed to control virus replication. We carried out a series of immunological and virological assays to understand why these Gag-specific CD8+ T cells could not control virus replication in vivo. GagCM9-specific CD8+ T cells from all of the animals were multifunctional and were found in the colonic mucosa. Additionally, GagCM9-specific CD8+ T cells accessed B cell follicles, the primary residence of SIV-infected cells in lymph nodes, with effector to target ratios between 20-250 GagCM9-specific CD8+ T cells per SIV-producing cell. Interestingly, vaccinated animals had few public TCR clonotypes within the GagCM9-specific CD8+ T cell population preand post-infection. The number of public TCR clonotypes expressed by GagCM9-specific CD8+ T cells post-infection significantly inversely correlated with chronic phase viral load. It is possible that these seven animals failed to control viral replication because of the narrow TCR repertoire expressed by the GagCM9-specific CD8+ T cell population elicited by vaccination and infection. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
26. Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral Infection.
- Author
-
Qingsheng Li, Skinner, Pamela J., Sang-Jun Ha, Duan, Lijie, Mattila, Teresa L., Hage, Aaron, White, Cara, Barber, Daniel L., O'Mara, Leigh, Southern, Peter J., Reilly, Cavan S., Carlis, John V., Miller, Christopher J., Ahmed, Rafi, and Haase, Ashley T.
- Subjects
- *
ANTIGENS , *VIRUS diseases , *IMMUNE response , *CELLS , *HIV infections , *SIMIAN viruses , *LYMPHOCYTIC choriomeningitis virus - Abstract
In the early stages of viral infection, outcomes depend on a race between expansion of infection and the immune response generated to contain it. We combined in situ tetramer staining with in situ hybridization to visualize, map, and quantify relationships between immune effector cells and their targets in tissues. In simian immunodeficiency virus infections in macaques and lymphocytic choriomeningitis virus infections in mice, the magnitude and timing of the establishment of ah excess of effector cells versus targets were found to correlate with the extent of control and the infection outcome (i.e., control and clearance versus partial or poor control and persistent infection). This method highlights the importance of the location, timing, and magnitude of the immune response needed for a vaccine to be effective against agents of persistent infection, such as HIV-1. [ABSTRACT FROM AUTHOR]
- Published
- 2009
27. Localized Populations of CD8low/- MHC Class I Tetramer+ SIV-Specific T Cells in Lymphoid Follicles and Genital Epithelium.
- Author
-
Jung Joo Hong, Reynolds, Matthew R., Mattila, Teresa L., Hage, Aaron, Watkins, David I., Miller, Christopher J., and Skinner, Pamela J.
- Subjects
T cells ,LYMPHOCYTES ,CELL-mediated lympholysis ,SUPPRESSOR cells ,LYMPHOID tissue ,IMMUNE system ,LYMPHATICS ,IMMUNOGLOBULINS ,EPITHELIUM - Abstract
CD8 T cells play an important role in controlling viral infections. We investigated the in situ localization of simian immunodeficiency virus (SIV)-specific T cells in lymph and genital tissues from SIV-infected macaques using MHC-class I tetramers. The majority of tetramer-binding cells localized in T cell zones and were CD8
+ . Curiously, small subpopulations of tetramer-binding cells that had little to no surface CD8 were detected in situ both early and late post-infection, and in both vaginally and rectally inoculated macaques. These tetramer+ CD8low/- cells were more often localized in apparent B cell follicles relative to T cell zones and more often found near or within the genital epithelium than the submucosa. Cells analyzed by flow cytometry showed similar populations of cells. Further immunohistological characterization revealed small populations of tetramer+ CD20- cells inside B cell follicles and that tetramer+ cells did not stain with γδ-TCR nor CD4 antibodies. Negative control tetramer staining indicated that tetramer+CD8low/2 cells were not likely NK cells nonspecifically binding to MHC tetramers. These findings have important implications for SIV-specific and other antigen-specific T cell function in these specific tissue locations, and suggest a model in which antigen-specific CD8+ T cells down modulate CD8 upon entering B cell follicles or the epithelial layer of tissues, or alternatively a model in which only antigen-specific CD8 T cells that down-modulate CD8 can enter B cell follicles or the epithelium. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
28. Allogeneic Lymphocytes Persist and Traffic in Feral MHCMatched Mauritian Cynomolgus Macaques.
- Author
-
Greene, Justin M., Burwitz, Benjamin J., Blasky, Alex J., Mattila, Teresa L., Jung Joo Hong, Rakasz, Eva G., Wiseman, Roger W., Hasenkrug, Kim J., Skinner, Pamela J., O'Connor, Shelby L., and O'Connor, David H.
- Subjects
MACAQUES ,FRIEND virus ,HIV ,SIMIAN immunodeficiency virus ,IMMUNOLOGIC diseases ,LYMPHOCYTES ,T cells ,PATHOGENIC microorganisms ,IMMUNE response - Abstract
Background: Thus far, live attenuated SIV has been the most successful method for vaccinating macaques against pathogenic SIV challenge; however, it is not clear what mechanisms are responsible for this protection. Adoptive transfer studies in mice have been integral to understanding live attenuated vaccine protection in models like Friend virus. Previous adoptive transfers in primates have failed as transferred cells are typically cleared within hours after transfer. Methodology/ Principal Findings: Here we describe adoptive transfer studies in Mauritian origin cynomolgus macaques (MCM), a non-human primate model with limited MHC diversity. Cells transferred between unrelated MHC-matched macaques persist for at least fourteen days but are rejected within 36 hours in MHC-mismatched macaques. Cells trafficked from the blood to peripheral lymphoid tissues within 12 hours of transfer. Conclusions/Significance: MHC-matched MCM provide the first viable primate model for adoptive transfer studies. Because macaques infected with SIV are the best model for HIV/AIDS pathogenesis, we can now directly study the correlates of protective immune responses to AIDS viruses. For example, plasma viral loads following pathogenic SIV challenge are reduced by several orders of magnitude in macaques previously immunized with attenuated SIV. Adoptive transfer of lymphocyte subpopulations from vaccinated donors into SIV-naïve animals may define the immune mechanisms responsible for protection and guide future vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. Prion disease induced alterations in gene expression in spleen and brain prior to clinical symptoms.
- Author
-
Kim, Hyeon O., Snyder, Greg P., Blazey, Tyler M., Race, Richard E., Chesebro, Bruce, and Skinner, Pamela J.
- Published
- 2008
30. In situ tetramer staining
- Author
-
Skinner, Pamela J. and Haase, Ashley T.
- Subjects
- *
MAJOR histocompatibility complex , *STAINS & staining (Microscopy) , *IMMUNOHISTOCHEMISTRY techniques - Abstract
The development of MHC tetramer staining has opened the doors to multiple avenues of new research [Science 274 (1996) 94]. In this review, we will discuss the development and application of in situ MHC tetramer (IST) staining. We describe two independently developed IST staining methodologies and discuss current uses, limitations, future uses and the interesting biology revealed by the use of IST staining. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
31. Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7.
- Author
-
Kaytor, Michael D., Duvick, Lisa A., Skinner, Pamela J., Koob, Michael D., Ranum, Laura P. W., and Orr, Harry T.
- Abstract
Spinocerebellar ataxia type 7 (SCA7) belongs to a group of neurological disorders caused by a CAG repeat expansion in the coding region of the associated gene. To gain insight into the pathogenesis of SCA7 and possible functions of ataxin-7, we examined the subcellular localization of ataxin-7 in transfected COS-1 cells using SCA7 cDNA clones with different CAG repeat tract lengths. In addition to a diffuse distribution throughout the nucleus, ataxin-7 associated with the nuclear matrix and the nucleolus. The location of the putative SCA7 nuclear localization sequence (NLS) was confirmed by fusing an ataxin-7 fragment with the normally cytoplasmic protein chicken muscle pyruvate kinase. Mutation of this NLS prevented protein from entering the nucleus. Thus, expanded ataxin-7 may carry out its pathogenic effects in the nucleus by altering a matrix-associated nuclear structure and/or by disrupting nucleolar function. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
32. Ataxin-1 Nuclear Localization and Aggregation: Role in Polyglutamine-Induced Disease in SCA1...
- Author
-
Klement, Ivan A. and Skinner, Pamela J.
- Subjects
- *
FRIEDREICH'S ataxia , *TRANSGENIC mice - Abstract
Examines the importance of nuclear localization and aggregation in pathogenesis through the use of transgenic mice carrying the spinocerebellar ataxia type 1 (SCA1) gene. Overview of the study; Results; Discussion; Experimental procedures.
- Published
- 1998
- Full Text
- View/download PDF
33. Ataxin-1 Nuclear Localization and Aggregation Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice
- Author
-
Klement, Ivan A, Skinner, Pamela J, Kaytor, Michael D, Yi, Hong, Hersch, Steven M, Clark, H.Brent, Zoghbi, Huda Y, and Orr, Harry T
- Abstract
Transgenic mice carrying the spinocerebellar ataxia type 1 (SCA1) gene, a polyglutamine neurodegenerative disorder, develop ataxia with ataxin-1 localized to aggregates within cerebellar Purkinje cells nuclei. To examine the importance of nuclear localization and aggregation in pathogenesis, mice expressing ataxin-1[82] with a mutated NLS were established. These mice did not develop disease, demonstrating that nuclear localization is critical for pathogenesis. In a second series of transgenic mice, ataxin-1[77] containing a deletion within the self-association region was expressed within Purkinje cells nuclei. These mice developed ataxia and Purkinje cell pathology similar to the original SCA1 mice. However, no evidence of nuclear ataxin-1 aggregates was found. Thus, although nuclear localization of ataxin-1 is necessary, nuclear aggregation of ataxin-1 is not required to initiate pathogenesis in transgenic mice.
- Full Text
- View/download PDF
34. Detection of Antigen-Specific T Cells Using In Situ MHC Tetramer Staining.
- Author
-
Abdelaal, Hadia M., Cartwright, Emily K., and Skinner, Pamela J.
- Subjects
T cells ,MAJOR histocompatibility complex ,BACTERIAL diseases ,VIRUS diseases ,IMMUNE response - Abstract
The development of in situ major histocompatibility complex (MHC) tetramer (IST) staining to detect antigen (Ag)-specific T cells in tissues has radically revolutionized our knowledge of the local cellular immune response to viral and bacterial infections, cancers, and autoimmunity. IST combined with immunohistochemistry (IHC) enables determination of the location, abundance, and phenotype of T cells, as well as the characterization of Ag-specific T cells in a 3-dimensional space with respect to neighboring cells and specific tissue locations. In this review, we discuss the history of the development of IST combined with IHC. We describe various methods used for IST staining, including direct and indirect IST and IST performed on fresh, lightly fixed, frozen, and fresh then frozen tissue. We also describe current applications for IST in viral and bacterial infections, cancer, and autoimmunity. IST combined with IHC provides a valuable tool for studying and tracking the Ag-specific T cell immune response in tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Cover Image.
- Author
-
Skinner, Pamela J.
- Subjects
- *
HIV infections , *CELLULAR therapy - Abstract
The cover image is based on the Invited Review Targeting reservoirs of HIV replication in lymphoid follicles with cellular therapies to cure HIV by Pamela J. Skinner, DOI: 10.1002/acg2.27 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. Targeting reservoirs of HIV replication in lymphoid follicles with cellular therapies to cure HIV.
- Author
-
Skinner, Pamela J.
- Subjects
- *
CELLULAR therapy , *HIV infections , *IMMUNOTHERAPY - Abstract
There is a need to create improved treatments for HIV infection. Growing evidence indicates that HIV treatment strategies must target and reduce viral replication in lymphoid follicles where HIV replication is most concentrated. In this mini‐review, three cell therapy approaches are described: CAR‐T and CAR‐NK cells, adoptive transfer of autologous HIV‐specific T cells, and HIV‐resistant cells. The potential for these innovative strategies to reduce viral replication in follicles and the potential of combining cell therapies with other treatment strategies to achieve a complete eradication of HIV is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection.
- Author
-
Miles, Brodie, Miller, Shannon M., Folkvord, Joy M., Kimball, Abigail, Chamanian, Mastooreh, Meditz, Amie L., Arends, Tessa, McCarter, Martin D., Levy, David N., Rakasz, Eva G., Skinner, Pamela J., and Connick, Elizabeth
- Subjects
HIV ,SIMIAN immunodeficiency virus ,LYMPHOID tissue ,HUMORAL immunity ,T cells - Abstract
Human and simian immunodeficiency viruses (HIV and SIV) exploit follicular lymphoid regions by establishing high levels of viral replication and dysregulating humoral immunity. Follicular regulatory T cells (T
FR ) are a recently characterized subset of lymphocytes that influence the germinal centre response through interactions with follicular helper T cells (TFH ). Here, utilizing both human and rhesus macaque models, we show the impact of HIV and SIV infection on TFR number and function. We find that TFR proportionately and numerically expand during infection through mechanisms involving viral entry and replication, TGF-β signalling, low apoptosis rates and the presence of regulatory dendritic cells. Further, TFR exhibit elevated regulatory phenotypes and impair TFH functions during HIV infection. Thus, TFR contribute to inefficient germinal centre responses and inhibit HIV and SIV clearance. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
38. With Minimal Systemic T-Cell Expansion, CD8+ T Cells Mediate Protection of Rhesus Macaques Immunized with Attenuated Simian-Human Immunodeficiency Virus SHIV89.6 from Vaginal Challenge with Simian Immunodeficiency Virus.
- Author
-
Genescà, Meritxell, Skinner, Pamela J., Jung Joo Hong, Jun Li, Ding Lu, McChesney, Michael B., and Miller, Christopher J.
- Subjects
- *
T cells , *CD antigens , *RHESUS monkeys , *IMMUNIZATION , *SIMIAN viruses , *HIV , *LYMPHOCYTES , *DISEASES - Abstract
The presence, at the time of challenge, of antiviral effector T cells in the vaginal mucosa of female rhesus macaques immunized with live-attenuated simian-human immunodeficiency virus 89.6 (SHIV89.6) is associated with consistent and reproducible protection from pathogenic simian immunodeficiency virus (SIV) vaginal challenge (18). Here, we definitively demonstrate the protective role of the SIV-specific CD8+ T-cell response in SHIV-immunized monkeys by CD8+ lymphocyte depletion, an intervention that abrogated SHIV-mediated control of challenge virus replication and largely eliminated the SIV-specific T-cell responses in blood, lymph nodes, and genital mucosa. While in the T-cell-intact SHIV-immunized animals, polyfunctional and degranulating SIV-specific CD8+ T cells were present in the genital tract and lymphoid tissues from the day of challenge until day 14 postchallenge, strikingly, expansion of SIV-specific CD8+ T cells in the immunized monkeys was minimal and limited to the vagina. Thus, protection from uncontrolled SIV replication in animals immunized with attenuated SHIV89.6 is primarily mediated by CD8+ T cells that do not undergo dramatic systemic expansion after SIV challenge. These findings demonstrate that despite, and perhaps because of, minimal systemic expansion of T cells at the time of challenge, a stable population of effector-cytotoxic CD8+ T cells can provide significant protection from vaginal SIV challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
39. Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency VirusPositive Macaques Treated with N-803.
- Author
-
Harwood, Olivia E., Balgeman, Alexis J., Weaver, Abigail J., Ellis-Connell, Amy L., Weiler, Andrea M., Erickson, Katrina N., Matschke, Lea M., Golfinos, Athena E., Vezys, Vaiva, Skinner, Pamela J., Safrit, Jeffrey T., Edlefsen, Paul T., Reynolds, Matthew R., Friedrich, Thomas C., and O’Connor, Shelby L.
- Subjects
- *
T cells , *MACAQUES , *VACCINIA , *HIV , *FOOT & mouth disease , *VESICULAR stomatitis , *VACCINATION - Abstract
Vaccine strategies aimed at eliciting human immunodeficiency virus (HIV)-specific CD8+ T cells are one major target of interest in HIV functional cure strategies. We hypothesized that CD8+ T cells elicited by therapeutic vaccination during antiretroviral therapy (ART) would be recalled and boosted by treatment with the interleukin 15 (IL-15) superagonist N-803 after ART discontinuation. We intravenously immunized four simian immunodeficiency virus-positive (SIV1) Mauritian cynomolgus macaques receiving ART with vesicular stomatitis virus (VSV), modified vaccinia virus Ankara strain (MVA), and recombinant adenovirus serotype 5 (rAd-5) vectors all expressing SIVmac239 Gag. Immediately after ART cessation, these animals received three doses of N-803. Four control animals received no vaccines or N-803. The vaccine regimen generated a high-magnitude response involving Gag-specific CD8+ T cells that were proliferative and biased toward an effector memory phenotype. We then compared cells elicited by vaccination (Gag specific) to cells elicited by SIV infection and unaffected by vaccination (Nef specific). We found that N-803 treatment enhanced the frequencies of both bulk and proliferating antigen-specific CD8+ T cells elicited by vaccination and the antigen-specific CD8+ T cells elicited by SIV infection. In sum, we demonstrate that a therapeutic heterologous prime-boost-boost (HPBB) vaccine can elicit antigen-specific effector memory CD8+ T cells that are boosted by N-803. IMPORTANCE While antiretroviral therapy (ART) can suppress HIV replication, it is not a cure. It is therefore essential to develop therapeutic strategies to enhance the immune system to better become activated and recognize virus-infected cells. Here, we evaluated a novel therapeutic vaccination strategy delivered to SIV+ Mauritian cynomolgus macaques receiving ART. ART was then discontinued and we delivered an immunotherapeutic agent (N-803) after ART withdrawal with the goal of eliciting and boosting anti-SIV cellular immunity. Immunologic and virologic analysis of peripheral blood and lymph nodes collected from these animals revealed transient boosts in the frequency, activation, proliferation, and memory phenotype of CD4+ and CD8+ T cells following each intervention. Overall, these results are important in educating the field of the transient nature of the immunological responses to this particular therapeutic regimen and the similar effects of N-803 on boosting T cells elicited by vaccination or elicited naturally by infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo.
- Author
-
Shengbin Li, Folkvord, Joy M., Rakasz, Eva G., Abdelaal, Hadia M., Wagstaff, Reece K., Kovacs, Katalin J., Kim, Hyeon O., Sawahata, Ryoko, MaWhinney, Samantha, Masopust, David, Connick, Elizabeth, and Skinner, Pamela J.
- Subjects
- *
HIV , *SIMIAN immunodeficiency virus , *GERMINAL centers , *T cells , *B cells - Abstract
Human immunodeficiency virus (HIV)- and simian immunodeficiency virus (SIV)-specific CD8+ T cells are typically largely excluded from lymphoid B cell follicles, where HIV- and SIV-producing cells are most highly concentrated, indicating that B cell follicles are somewhat of an immunoprivileged site. To gain insights into virus-specific follicular CD8+ T cells, we determined the location and phenotype of follicular SIV-specific CD8+ T cells in situ, the local relationship of these cells to Foxp3+ cells, and the effects of CD8 depletion on levels of follicular SIV-producing cells in chronically SIV-infected rhesus macaques. We found that follicular SIV-specific CD8+ T cells were able to migrate throughout follicular areas, including germinal centers. Many expressed PD-1, indicating that they may have been exhausted. A small subset was in direct contact with and likely inhibited by Foxp3+ cells, and a few were themselves Foxp3+. In addition, subsets of follicular SIV-specific CD8+ T cells expressed low to medium levels of perforin, and subsets were activated and proliferating. Importantly, after CD8 depletion, the number of SIVproducing cells increased in B cell follicles and extrafollicular areas, suggesting that follicular and extrafollicular CD8+ T cells have a suppressive effect on SIV replication. Taken together, these results suggest that during chronic SIV infection, despite high levels of exhaustion and likely inhibition by Foxp3+ cells, a subset of follicular SIV-specific CD8+ T cells are functional and suppress viral replication in vivo. These findings support HIV cure strategies that augment functional follicular virus-specific CD8+ T cells to enhance viral control. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Compartmentalization of Simian Immunodeficiency Virus Replication within Secondary Lymphoid Tissues of Rhesus Macaques Is Linked to Disease Stage and Inversely Related to Localization of Virus-Specific CTL.
- Author
-
Connick, Elizabeth, Folkvord, Joy M., Lind, Katherine T., Rakasz, Eva G., Miles, Brodie, Wilson, Nancy A., Santiago, Mario L., Schmitt, Kimberly, Stephens, Edward B., Kim, Hyeon O., Wagstaff, Reece, Li, Shengbin, Abdelaal, Hadia M., Kemp, Nathan, Watkins, David I., MaWhinney, Samantha, and Skinner, Pamela J.
- Subjects
- *
LYMPHOID tissue , *LYMPH nodes , *B cells , *ESTRONE , *FOLLICULAR dendritic cells , *IMMUNODEFICIENCY , *IMMUNOSUPPRESSION - Abstract
We previously demonstrated that HIV replication is concentrated in lymph node B cell follicles during chronic infection and that HIV-specific CTL fail to accumulate in large numbers at those sites. It is unknown whether these observations can be generalized to other secondary lymphoid tissues or whether virus compartmentalization occurs in the absence of CTL. We evaluated these questions in SIVmac239-infected rhesus macaques by quantifying SIV RNA+ cells and SIV-specific CTL in situ in spleen, lymph nodes, and intestinal tissues obtained at several stages of infection. During chronic asymptomatic infection prior to simian AIDS, SIV-producing cells were more concentrated in follicular (F) compared with extrafollicular (EF) regions of secondary lymphoid tissues. At day 14 of infection, when CTL have minimal impact on virus replication, there was no compartmentalization of SIV-producing cells. Virus compartmentalization was diminished in animals with simian AIDS, which often have low-frequency CTL responses. SIV-specific CTL were consistently more concentrated within EF regions of lymph node and spleen in chronically infected animals regardless of epitope specificity. Frequencies of SIV-specific CTL within F and EF compartments predicted SIV RNA+ cells within these compartments in a mixed model. Few SIV-specific CTL expressed the F homing molecule CXCR5 in the absence of the EF retention molecule CCR7, possibly accounting for the paucity of F CTL. These findings bolster the hypothesis that B cell follicles are immune privileged sites and suggest that strategies to augment CTL in B cell follicles could lead to improved viral control and possibly a functional cure for HIV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Local Antibody Production and Concentration on the Path of Virus Entry.
- Author
-
Qingsheng Li, Ming Zeng, Lijie Duan, Voss, James E., Smith, Anthony J., Pambuccian, Stefan, Liang Shang, Wietgrefe, Stephen, Southern, Peter J., Reilly, Cavan S., Skinner, Pamela J., Zupancic, Mary L., Carlis, John V., Piatak Jr., Michael, Waterman, Diane, Reeves, R. Keith, Masek-Hammerman, Katherine, Derdeyn, Cynthia A., Alpert, Michael D., and Evans, David T.
- Subjects
- *
HIV infection transmission , *AIDS vaccines , *VIRAL vaccines , *ECTOPIC tissue , *GLYCOPROTEINS - Abstract
We sought design principles for a vaccine to prevent HIV transmission to women by identifying correlates of protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal model. We show that SIVmac239Δnef vaccination recruits plasma cells and induces ectopic lymphoid follicle formation beneath the mucosal epithelium in the rhesus macaque female reproductive tract. The plasma cells and ectopic follicles produce IgG Abs reactive with viral envelope glycoprotein gp41 trimers, and these Abs are concentrated on the path of virus entry by the neonatal FcR in cervical reserve epithelium and in vaginal epithelium. This local Ab production and delivery system correlated spatially and temporally with the maturation of local protection against high-dose pathogenic SIV vaginal challenge. Thus, designing vaccines to elicit production and concentration of Abs at mucosal frontlines could aid in the development of an effective vaccine to protect women against HIV-1. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. CD8+ T-Lymphocyte Response to Major Immunodominant Epitopes after Vaginal Exposure to Simian Immunodeficiency Virus: Too Late and Too Little.
- Author
-
Reynolds, Matthew R., Rakasz, Eva, Skinner, Pamela J., White, Cara, Abel, Kristina, Zhong-Min Ma, Compton, Lara, Napoé, Gnankang, Wilson, Nancy, Miller, Christopher J., Haase, Ashley, and Watkins, David I.
- Subjects
- *
HIV , *SIMIAN viruses , *SEXUALLY transmitted diseases , *T cells , *LYMPHOCYTES - Abstract
In the acute stage of infection following sexual transmission of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV), virus-specific CD8+ T-lymphocyte responses partially control but do not eradicate infection from the lymphatic tissues (LTs) or prevent the particularly massive depletion of CD4+ T lymphocytes in gut-associated lymphatic tissue (GALT). We explored hypothetical explanations for this failure to clear infection and prevent CD4+ T-lymphocyte loss in the SIV/rhesus macaque model of intravaginal transmission. We examined the relationship between the timing and magnitude of the CD8+ T-lymphocyte response to immunodominant SIV epitopes and viral replication, and we show first that the failure to contain infection is not because the female reproductive tract is a poor inductive site. We documented robust responses in cervicovaginal tissues and uterus, but only several days after the peak of virus production. Second, while we also documented a modest response in the draining genital and peripheral lymph nodes, the response at these sites also lagged behind peak virus production in these LT compartments. Third, we found that the response in GALT was surprisingly low or undetectable, possibly contributing to the severe and sustained depletion of CD4+ T lymphocytes in the GALT. Thus, the virus-specific CD8+ T-lymphocyte response is "too late and too little" to clear infection and prevent CD4+ T-lymphocyte loss. However, the robust response in female reproductive tissues may be an encouraging sign that vaccines that rapidly induce high-frequency CD8+ T-lymphocyte responses might be able to prevent acquisition of HIV-1 infection by the most common route of transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
44. Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells.
- Author
-
Davey BC, Pampusch MS, Cartwright EK, Abdelaal HM, Rakasz EG, Rendahl A, Berger EA, and Skinner PJ
- Subjects
- Animals, Antibodies therapeutic use, Antibody Formation, CD28 Antigens, Macaca mulatta, Simian Immunodeficiency Virus, Receptors, Chimeric Antigen, Simian Acquired Immunodeficiency Syndrome therapy, Immunotherapy
- Abstract
T cells expressing a simian immunodeficiency (SIV)-specific chimeric antigen receptor (CAR) and the follicular homing molecule, CXCR5, were infused into antiretroviral therapy (ART) suppressed, SIV-infected rhesus macaques to assess their ability to localize to the lymphoid follicle and control the virus upon ART interruption. While the cells showed evidence of functionality, they failed to persist in the animals beyond 28 days. Development of anti-CAR antibodies could be responsible for the lack of persistence. Potential antigenic sites on the anti-SIV CAR used in these studies included domains 1 and 2 of CD4, the carbohydrate recognition domain (CRD) of mannose-binding lectin (MBL), and an extracellular domain of the costimulatory molecule, CD28, along with short linker sequences. Using a flow cytometry based assay and target cells expressing the CAR/CXCR5 construct, we examined the serum of the CD4-MBL CAR/CXCR5-T cell treated animals to determine that the animals had developed an anti-CAR antibody response after infusion. Binding sites for the anti-CAR antibodies were identified by using alternative CARs transduced into target cells and by preincubation of the target cells with a CD4 blocking antibody. All of the treated animals developed antibodies in their serum that bound to CD4-MBL CAR/CXCR5 T cells and the majority were capable of inducing an ADCC response. The CD4 antibody-blocking assay suggests that the dominant immunogenic components of this CAR are the CD4 domains with a possible additional site of the CD28 domain with its linker. This study shows that an anti-drug antibody (ADA) response can occur even when using self-proteins, likely due to novel epitopes created by abridged self-proteins and/or the self-domain of the CAR connection to a small non-self linker. While in our study, there was no statistically significant correlation between the ADA response and the persistence of the CD4-MBL CAR/CXCR5-T cells in rhesus macaques, these findings suggest that the development of an ADA response could impact the long-term persistence of self-based CAR immunotherapies., Competing Interests: PS is the cofounder and CSO of MarPam Pharma and has a patent pending US20180371057A1. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor JD declared a shared affiliation with the author EB at the time of review., (Copyright © 2022 Davey, Pampusch, Cartwright, Abdelaal, Rakasz, Rendahl, Berger and Skinner.)
- Published
- 2022
- Full Text
- View/download PDF
45. HIV-Specific CAR T Cells with CD28 or 4-1BB Signaling Domains Are Phenotypically and Functionally Distinct and Effective at Suppressing HIV and Simian Immunodeficiency Virus.
- Author
-
Cartwright EK, Pampusch MS, Rendahl AK, Berger EA, Coleman-Fuller N, and Skinner PJ
- Subjects
- Animals, Antiviral Agents, CD28 Antigens, Humans, Macaca mulatta, HIV Infections therapy, Receptors, Chimeric Antigen, Simian Immunodeficiency Virus
- Abstract
Despite mounting a robust antiviral CD8 T cell response to HIV infection, most infected individuals are unable to control HIV viral load without antiretroviral therapy (ART). Chimeric Ag receptor (CAR) T cell treatment is under intensive investigation as an alternative therapy for ART-free remission of chronic HIV infection. However, achieving durable remission of HIV will require a successful balance between CAR T cell effector function and persistence. CAR T cells with CD28 costimulatory domains have robust effector function but limited persistence in vivo, whereas CAR T cells with 4-1BB costimulatory domains present a more undifferentiated phenotype and greater in vivo persistence. We compared the in vitro phenotype and function of rhesus macaque and human CAR T cells that contained either the CD28 or 4-1BB costimulatory domain; both constructs also included CARs that are bispecific for gp120 of HIV or SIV and the CXCR5 moiety to promote in vivo homing of CAR/CXCR5 T cells to B cell follicles. Cells were transduced using a gammaretroviral vector and evaluated using flow cytometry. 4-1BB-CAR/CXCR5 T cells were phenotypically distinct from CD28-CAR/CXCR5 T cells and showed increased expression of CAR and CD95. Importantly, both CD28- and 4-1BB-CAR/CXCR5 T cells retained equal capacity to recognize and suppress SIV in vitro. These studies provide new insights into rhesus macaque and human 4-1BB- and CD28-bearing CAR T cells., (Copyright © 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
46. Production and Characterization of SIV-Specific CAR/CXCR5 T Cells.
- Author
-
Pampusch MS, Hajduczki A, Mwakalundwa G, Connick E, Berger EA, and Skinner PJ
- Subjects
- Animals, CD8-Positive T-Lymphocytes, HIV Infections, Leukocytes, Mononuclear, Macaca mulatta, Receptors, CXCR5 genetics, Simian Immunodeficiency Virus, T-Lymphocytes
- Abstract
HIV-specific chimeric antigen receptor (CAR) T cells that target lymphoid follicles have the potential to functionally cure HIV infection. CD8
+ T cells, NK cells, or peripheral blood mononuclear cells (PBMC) may be modified to express HIV-specific CARs as well as follicular homing molecules such as CXCR5 to target the virally infected T follicular helper cells that concentrate within B cell follicles during HIV infection. This chapter outlines methods utilizing a simian immunodeficiency virus (SIV) rhesus macaque model of HIV to produce transduced T cells from primary PBMCs. Methods are presented for production of an SIV-specific CAR/CXCR5-encoding retrovirus used to transduce primary rhesus macaque PBMCs. Procedures to evaluate the functionality of the expanded CAR/CXCR5 T cells in vitro and ex vivo are also presented. An in vitro migration assay determines the ability of the T cells expressing CAR/CXCR5 to migrate to the CXCR5 ligand CXCL13, while an ex vivo migration assay allows measurement of the transduced T cell migration into the B cell follicle. Antiviral activity of the CAR/CXCR5 transduced T cells is determined using a viral suppression assay. These methods can be used to produce T cells for immunotherapy in SIV-infected rhesus macaques and to evaluate the functionality of the cells prior to infusion. Similar procedures can be used to produce HIV-specific CAR/CXCR5 T cells., (© 2022. Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
47. Antigenic cells augment CAR T cells.
- Author
-
Skinner PJ
- Subjects
- Animals, Primates, T-Lymphocytes, HIV Infections, Receptors, Antigen, T-Cell genetics
- Published
- 2020
- Full Text
- View/download PDF
48. Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype.
- Author
-
Pampusch MS and Skinner PJ
- Subjects
- Cell Culture Techniques, Cell Survival, Immunotherapy, Adoptive, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism, Phenotype, Receptors, Antigen, T-Cell metabolism, Receptors, CXCR5 genetics, Receptors, CXCR5 metabolism, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen metabolism, T-Lymphocytes metabolism, Transduction, Genetic, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Emerging immunotherapies to treat infectious diseases and cancers often involve transduction of cellular populations with genes encoding disease-targeting proteins. For example, chimeric antigen receptor (CAR)-T cells to treat cancers and viral infections involve the transduction of T cells with synthetic genes encoding CAR molecules. The CAR molecules make the T cells specifically recognize and kill cancer or virally infected cells. Cells can also be co-transduced with other genes of interest. For example, cells can be co-transduced with genes encoding proteins that target cells to specific locations. Here, we present a protocol to transduce primary peripheral blood mononuclear cells (PBMCs) with genes encoding a virus-specific CAR and the B cell follicle homing molecule chemokine receptor type 5 (CXCR5). This procedure takes nine days and results in transduced T cell populations that maintain a central memory phenotype. Maintenance of a central memory or less differentiated phenotype has been shown to associate with persistence of cells post-infusion. Furthermore, cells produced with this method show high levels of viability, high levels of co-expression of the two transduced genes, and large enough quantities of cells for immunotherapeutic infusion. This nine-day protocol may be broadly used for CAR-T cell and other T cell immunotherapy approaches. The methods described here are based on studies presented in our previous publications.
- Published
- 2020
- Full Text
- View/download PDF
49. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.
- Author
-
Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, and Sacha JB
- Subjects
- Animals, B-Lymphocytes cytology, B-Lymphocytes immunology, CD8-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes immunology, Cell Movement drug effects, Disease Models, Animal, HIV Infections genetics, HIV Infections immunology, HIV Infections physiopathology, HIV-1 drug effects, HIV-1 physiology, Humans, Interleukin-15 genetics, Interleukin-15 immunology, Killer Cells, Natural cytology, Killer Cells, Natural immunology, Lymph Nodes drug effects, Lymph Nodes immunology, Macaca mulatta, Recombinant Fusion Proteins, Simian Acquired Immunodeficiency Syndrome drug therapy, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome physiopathology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus drug effects, Simian Immunodeficiency Virus physiology, Virus Latency drug effects, Anti-Retroviral Agents administration & dosage, B-Lymphocytes drug effects, CD8-Positive T-Lymphocytes drug effects, HIV Infections drug therapy, Interleukin-15 antagonists & inhibitors, Killer Cells, Natural drug effects, Proteins administration & dosage
- Abstract
Despite the success of antiretroviral therapy (ART) to halt viral replication and slow disease progression, this treatment is not curative and there remains an urgent need to develop approaches to clear the latent HIV reservoir. The human IL-15 superagonist N-803 (formerly ALT-803) is a promising anti-cancer biologic with potent immunostimulatory properties that has been extended into the field of HIV as a potential "shock and kill" therapeutic for HIV cure. However, the ability of N-803 to reactivate latent virus and modulate anti-viral immunity in vivo under the cover of ART remains undefined. Here, we show that in ART-suppressed, simian-human immunodeficiency virus (SHIV)SF162P3-infected rhesus macaques, subcutaneous administration of N-803 activates and mobilizes both NK cells and SHIV-specific CD8+ T cells from the peripheral blood to lymph node B cell follicles, a sanctuary site for latent virus that normally excludes such effector cells. We observed minimal activation of memory CD4+ T cells and no increase in viral RNA content in lymph node resident CD4+ T cells post N-803 administration. Accordingly, we found no difference in the number or magnitude of plasma viremia timepoints between treated and untreated animals during the N-803 administration period, and no difference in the size of the viral DNA cell-associated reservoir post N-803 treatment. These results substantiate N-803 as a potent immunotherapeutic candidate capable of activating and directing effector CD8+ T and NK cells to the B cell follicle during full ART suppression, and suggest N-803 must be paired with a bona fide latency reversing agent in vivo to facilitate immune-mediated modulation of the latent viral reservoir., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Jeffrey Safrit is an employee of NantBioScience Inc./NantKWest LLC, the maker of N-803. Shiho Tanaka is an employee of ImmunityBio, a branch of NantKWest responsible for performing the ADA assay. No other authors have declared that competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
50. Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations.
- Author
-
Pampusch MS, Haran KP, Hart GT, Rakasz EG, Rendahl AK, Berger EA, Connick E, and Skinner PJ
- Abstract
Chimeric antigen receptor (CAR)-T cells show great promise in treating cancers and viral infections. However, most protocols developed to expand T cells require relatively long periods of time in culture, potentially leading to progression toward populations of terminally differentiated effector memory cells. Here, we describe in detail a 9-day protocol for CAR gene transduction and expansion of primary rhesus macaque peripheral blood mononuclear cells (PBMCs). Cells produced and expanded with this method show high levels of viability, high levels of co-expression of two transduced genes, retention of the central memory phenotype, and sufficient quantity for immunotherapeutic infusion of 1-2 × 10
8 cells/kg in a 10 kg rhesus macaque. This 9-day protocol may be broadly used for CAR-T cell and other T cell immunotherapy approaches to decrease culture time and increase maintenance of central memory populations., (© 2019 The Author(s).)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.